| アブストラクト | Antistaphylococcal penicillins such as nafcillin and oxacillin are among the first choices of treatment for severe invasive methicillin-susceptible Staphylococcus aureus (MSSA) infections, although there has been limited safety evaluations between individual agents. Using the FDA Adverse Event Reports System (FAERS), oxacillin was observed to have a lower proportion of reports of acute renal failure (reporting odds ratio [ROR], 5.3 [95% confidence interval {CI}, 3.1 to 9.3] versus 21.3 [95% CI, 15.8 to 28.6], respectively) and hypokalemia (ROR, 0.7 [95% CI, 0.1 to 4.8] versus 11.4 [95% CI, 7.1 to 18.3], respectively) than nafcillin. |
|---|
| ジャーナル名 | Antimicrobial agents and chemotherapy |
|---|
| Pubmed追加日 | 2019/12/18 |
|---|
| 投稿者 | Timbrook, Tristan T; McKay, Lydia; Sutton, Jesse D; Spivak, Emily S |
|---|
| 組織名 | Department of Pharmacy, University of Utah, Salt Lake City, Utah, USA;Tristan.Timbrook@utah.edu.;Department of Pharmacy, University of Utah, Salt Lake City, Utah, USA.;Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, USA.;Department of Internal Medicine, Division of Infectious Diseases, University of;Utah School of Medicine, Salt Lake City, Utah, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31844017/ |
|---|
